Clinical-stage biotechnology company Pieris Pharmaceuticals Inc.’s Anticalin treatment suite to combat cancer, respiratory conditions and other maladies, recently obtained approval from Australian authorities to commence a first-time study for PRS-060/AZD1402, an inhaled treatment targeting asthma.
National Institutes of Health (NIH) and Case Western Reserve University School of Medicine researchers have released a study raising concerns over the transmission of prion diseases such as Creutzfeldt-Jakob disease (CJD) through the skin.
A recent study by researchers at the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center shows cognitive computing can help doctors find more clinical trials and therapeutic options for their cancer patients based on the genetic makeup of their tumors.
AstraZeneca and MedImmune, its department for global biologics research and development, recently gave 28 presentations at the American Heart Association (AHA) Scientific Sessions, which took place Nov. 11-15 in Anaheim, California.
Scientists from the University of North Carolina (UNC) and North Carolina State University have developed a melanin-enhanced cancer immunotherapy treatment that boosts a naturally occurring immune response against skin cancer cells in mice.
North Carolina’s Vidant Chowan Hospital and Vidant Roanoke-Chowan Hospital recently earned grants from the nonprofit North Carolina Stroke Association (NCSA) to fund programs for official stroke readiness certification.
University of North Carolina School of Medicine researchers have charted a revised model for cystic fibrosis (CF) patients that could help the scientific community better understand and treat the disorder, according to the university.
New surveys using data from ArthritisPower and CreakyJoints, part of the Global Healthy Living Foundation show women living with rheumatoid arthritis (RA) lack the information and resources to make confident decisions when it comes to reproductive health and family planning.
Scientists from New York-Presbyterian Hospital and Weill Cornell Medicine are calling for deeper clinical trials for newer, nonchemotherapy drugs that they say will benefit patients with mantle cell lymphoma (MCL), a blood cancer.